Regulators on both sides of the Atlantic just handed AstraZeneca Plc (AZN) a pair of wins that touch very different corners of medicine: a rare neuromuscular disease and a common, stubborn cancer.
The U.S. Food and Drug Administration and EU authorities on Monday approved Klygefa (gefurulimab) from Alexion, AstraZeneca Rare Disease, for adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). In the EU, the therapy got the green light as an add-on to standard treatment.
Klygefa is the first and only dual-binding nanobody C5 inhibitor, which is a fancy way of saying it blocks the complement system in two places. For patients, the practical perk is self-administration: a once-weekly subcutaneous injection via an autoinjector.
The approvals rest on the pivotal PREVAIL Phase 3 trial, which showed Klygefa improved Myasthenia Gravis Activities of Daily Living (MG-ADL) total scores at week 26 over placebo by a 1.6-point difference (p<0.0001), with clinical gains starting by week one. Regulators in China and additional nations are currently reviewing PREVAIL submissions.
FDA Clears Perioperative Imfinzi Regimen For Bladder Cancer
Then there's the oncology side. On Friday, the FDA granted Priority Review approval to AstraZeneca's Imfinzi (durvalumab) plus enfortumab vedotin (EV) before radical cystectomy, followed by Imfinzi monotherapy after bladder removal. The regimen is for adults with muscle-invasive bladder cancer (MIBC) who refuse or cannot take cisplatin-based chemotherapy.
That's a meaningful slice of patients. Roughly 16,000 U.S. patients will undergo MIBC treatment in 2026, and up to 50% cannot tolerate cisplatin due to kidney impairment or comorbidities.
The VOLGA Phase 3 trial, presented at the 2026 ESMO Congress and published in The New England Journal of Medicine, showed the perioperative regimen cut the risk of progression, recurrence, missed surgery, or death by 49% versus surgery with or without approved adjuvant therapy (HR 0.51; p<0.0001). It also lowered death risk by 42% (HR 0.58; p=0.0027), keeping 78% of patients alive at two years versus 69%, and 64% event-free versus 45%.
AZN Price Action: AstraZeneca shares were up 0.73% at $185.78 during premarket trading on Monday, according to market data.